
NRSN Stock Forecast & Price Target
NRSN Analyst Ratings
Bulls say
NeuroSense Therapeutics is well-positioned to take advantage of the growing market for neurodegenerative disease treatments with its promising product candidate, PrimeC. Their focus on targeting neuroinflammation and lysosomal dysfunction sets them apart in the industry, and their strategic decision to combine two generic drugs has the potential to carve out a significant market share. Along with a Buy rating and a $8 price target, NeuroSense has projected blockbuster potential with estimated sales of $1 billion and a 20% market penetration.
Bears say
NeuroSense Therapeutics is a financially sound company with a promising drug candidate in PrimeC, but their current timeline for FDA approval and launch in 2027 and 2028, respectively, may not be aligned with the urgent needs for new treatments for neurodegenerative diseases. Additionally, the company's reliance on strategic resources and potential changes to their drug candidate could pose risks to their overall success.
This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.
NRSN Analyst Forecast & Price Prediction
Start investing in NRSN
Order type
Buy in
Order amount
Est. shares
0 shares